Home » Blog » Drug Costs, Patient-Generated Health Data, ACA Repeal, Multigene Testing, and Cancer Policy

Drug Costs, Patient-Generated Health Data, ACA Repeal, Multigene Testing, and Cancer Policy


IP Blog | Dave Melin | February 26, 2017

In this week’s BioBlog we look at how difficult it is for cancer patients to afford their medications and the difficult choices they face, the outlook for hospital in the potential ACA repeal and more.

Cancer Survivors Skip Prescription Drugs Due to Cost: Study

New research shows that cancer patients often skip doses or look for cheaper medications due to the high costs of cancer drugs.

6 Barriers to Use of Patient-Generated Health Data

A survey from Medscape indicates that patients feel that doctors are more engaged when they provide their health data at visits.

New York-Presbyterian’s Steven Corwin on What an ACA Repeal Means for Hospitals

Looking ahead to the expected repeal of the Affordable Care Act many uncertainties for hospitals lie ahead due to funding concerns.

Payers Weigh the Implications of Multigene Testing Coverage

In this article we look at the roadblocks that exist in getting multigene testing covered by insurance companies.

Cancer Policy Priorities for New Congress and Administration Take Center Stage in Meetings with Key Agencies and Hill Offices

ASCO’s government relations committee met with key members of the governments to discuss ASCO’s policy priorities.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *